Nasdaq GlobeNewswire

Taconic Biosciences Announces Partnership With Cergentis B.V. to Provide Transgene Mapping Services

Del

HUDSON, N.Y., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it has signed a collaborative agreement with Cergentis B.V. ("Cergentis") to leverage the company's Targeted Locus Amplification (TLA) technology to provide transgene mapping services to its customers.

While transgenic mice generated via random pro-nuclear injection (PNI) continue to be a critical tool in biomedical research, a distinct disadvantage of these models is the inability to direct the transgene to a specific integration site within the genome. Cergentis has developed a next generation sequencing method based on their patented TLA technology. Taconic's Transgene Mapping Analysis (TgMA) service leverages this platform, making the task of determining the precise location of a randomly inserted transgene much easier. In addition to the sequencing data from Cergentis, Taconic provides expert interpretation specific to the transgenic line, leading to an optimized breeding strategy.

"Cergentis TLA technology brings characterization of transgenic rodent models to a whole new level. This technology enables quick and reliable determination of transgene insertion site(s) while providing important data regarding the integrity of the transgene itself and potential disruption of endogenous genes. Taconic can now provide precise assessment of a transgenic model and use the TLA data to better plan intercrosses for future studies," shared Dr. Jochen Welcker, director of molecular biology and scientific development.

Cergentis CEO Max van Min comments: "Cergentis is delighted with this collaboration. Taconic is a leading supplier of rodent models and by leveraging both our expertise our common customers are served most effectively."

Taconic is a fully-licensed provider of rodent model generation services and has twenty years of model design experience. The company provides gene inactivation, gene mutation or replacement, transgene expression, RNAi, and gene editing via CRISPR-Cas9, pronuclear injection, and homologous recombination technologies to ensure that the right tools are leveraged for each specific customer project. Taconic's unique capability of providing a seamless transition from model design to breeding and colony management, offers customers a complete solution. These scientific services include acquiring or generating, importing, licensing, breeding, testing, preparing, and distributing genetically engineered models to any location worldwide.

Cergentis is based in the Netherlands and provides services and kits based on its proprietary Targeted Locus Amplification Technology. Uniquely, TLA enables targeted complete Next Generation Sequencing and the detection of all Single Nucleotide Variants and structural changes. Key applications of TLA include genetic diagnostics, oncogenetics, and sequencing of gene-editing events, transgenes and integration sites in amongst others plants, cells and animal models. Cergentis works for leading pharmaceutical companies and research institutes worldwide.

For more information contact info@cergentis.com.   

To learn more about Taconic's custom model generation, please call 1-888-TACONIC (888-822-6642) in the US, or +45 70 23 04 05 in Europe, or email info@taconic.com.  

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide.  Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Wabtec and GE Transportation to Merge, Creating Global Leader for Rail Equipment, Services and Software21.5.2018 13:00Pressemelding

Strategic Combination Will Drive Shareholder Value Creation by Accelerating Innovation in Transportation and Logistics Following the transaction, Wabtec will have approximately $8 billion in revenues, a more diversified business mix, higher margins, and approximately 15 percent cash EPS accretion in year one. Both businesses are expected to benefit from the cyclical tailwinds they are experiencing as industry conditions improve. Complementary businesses and large global installed base will create additional opportunities for cross-selling, aftermarket services growth and new solutions in a rapidly evolving industry. GE Transportation is positioned for a substantial rebound, with estimated adjusted EBITDA growing from about $750 million in 2018 to between $900 million and $1 billion in 2019. Substantial annual run-rate synergies of $250 million and a net present value of approximately $1.1 billion of net tax benefit will accrue to the combined company. The transaction is valued at appro

Sciaky Receives Order for Multiple Electron Beam Additive Manufacturing (EBAM®) Systems to Strengthen America's Defense and Power Generation Programs21.5.2018 09:00Pressemelding

CHICAGO, May 21, 2018 (GLOBE NEWSWIRE) -- Sciaky, Inc., a subsidiary of Phillips Service Industries, Inc. (PSI) and leading provider of metal additive manufacturing (AM) solutions, announced today that it has received an order for multiple Electron Beam Additive Manufacturing (EBAM®) systems to bolster the nation's defense and power generation programs. Details of the project are confidential. "Sciaky has a long history of providing innovative solutions to America's military and power generation initiatives," said Scott Phillips, President and CEO of Sciaky, Inc. "Our EBAM process is the only industrial-grade metal 3D printing technology to produce large-scale parts for land, sea, air, and space applications." As the most widely scalable metal additive manufacturing solution in the industry (in terms of work envelope), Sciaky's EBAM systems can produce parts ranging from 8 inches (203 mm) to 19 feet (5.79 meters) in length. EBAM is also the fastest deposition process in the metal addit

INTA Selects Singapore for 142nd Annual Meeting Slated for April 202021.5.2018 02:10Pressemelding

SEATTLE, May 20, 2018 (GLOBE NEWSWIRE) -- The International Trademark Association (INTA) today announced that it will hold its 142nd Annual Meeting-the world's largest trademark event-in Singapore from April 25 to 29, 2020, at the Marina Bay Sands. This marks the second time INTA is bringing its Annual Meeting to Asia, and the first time that the organization will host the event in Southeast Asia. INTA CEO Etienne Sanz de Acedo made the highly anticipated announcement at the opening ceremonies of the Association's 140th Annual Meeting, taking place in Seattle, Washington, now through May 23. Nearly 11,000 trademark practitioners and other intellectual property (IP) professionals from 150+ countries are gathering for this event. The number of registrants has been increasing each year. In 2014, INTA held its first-ever Annual Meeting in Asia-the 136th Annual Meeting in Hong Kong SAR, China. After that successful event, INTA's Board of Directors approved a rotation strategy to host the An

GlobeNewswire Test Release19.5.2018 07:00Pressemelding

LOS ANGELES, May 18, 2018 (GLOBE NEWSWIRE) -- This is a test from GlobeNewswire. Readers are advised to disregard. TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING -- TESTING – -END- CONTACT: Karen Yu Director, GlobeNewswire Product Management Direct: +1 310 258 6917 Mobile: +1 626 389 7427 or Magali Rolandez Senior Manager, Media Relations/Content Distribution Europe Direct: +44 (0) 203 753 2215 Mobile: +44 (0) 7785 619 539

BK Ultrasound, Powered by Analogic, Launches bkSpecto Ultrasound System for Urology at the 2018 American Urological Association Annual Meeting18.5.2018 23:23Pressemelding

PEABODY, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch the bkSpecto(TM) ultrasound system at the 113th AUA (American Urological Association) Annual Meeting, May 18-21, in San Francisco. bkSpecto-taken from the Latin word Specto, meaning 'I see'-is BK Ultrasound's all-new ultrasound platform designed for clinical practices. bkSpecto combines BK's advanced auto-optimization algorithms with faster processing to render exceptional anatomical imaging detail with minimal manual adjustment by the user. The system has a unique glass touch-based interface using BK's Tru-Sense(TM) technology to provide 'sightless navigation.' The interface enables tactile feedback with or without gloves, providing an intuitive, self-guided user experience. The interface is also customizable, enabling personalized and faster user workflows. The small footprint of bkSpecto makes

Brookfield Asset Management Announces Renewal of Normal Course Issuer Bid18.5.2018 12:55Pressemelding

TORONTO, May 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE:BAM) (TSX:BAM.A) (EURONEXT:BAMA) ("Brookfield") today announced it has received approval from the Toronto Stock Exchange ("TSX") for the renewal of its normal course issuer bid to purchase up to 82,315,909 Class A Limited Voting Shares ("Class A Shares"), representing 10% of the public float of Brookfield's outstanding Class A Shares. Purchases under the bid will be made through the facilities of the TSX, the New York Stock Exchange ("NYSE") and any alternative Canadian trading system. The period of the normal course issuer bid will extend from May 24, 2018 to May 23, 2019, or an earlier date should Brookfield complete its purchases. Brookfield will pay the market price at the time of acquisition for any Class A Shares purchased. As at May 1, 2018, the number of Class A Shares issued and outstanding totalled 991,857,711, of which 823,159,095 shares represented the public float. In accordance with the rules

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom